Free initial consultation 206.957.9510 888.647.6007
Bergman Draper & Frockt attorneys Matthew Bergman, Brian Weinstein, and Benjamin Couture served recently as guest lecturers at the University of Idaho College of Law in Moscow, Idaho. They spoke at an upper-level Remedies class on the subject of developing and eliciting damages testimony in personal injury cases. (more…)
Dr EgilmanDr. David Egilman is a Professor of Medicine at Brown University in Rhode in Rhode Island and the Editor-in-chief of the International Journal of Occupational and Environmental Health. He has very recently authored an article to appear in the next edition of his journal critiquing the in- court testimony of expert witnesses hired by asbestos companies to defeat lawsuits brought by mesothelioma victims.
Dr. Egilman makes it very clear that if the same rigorous standards that are applied to medical articles before they are published were applied to these expert’s testimony, their opinions would not hold water.
When people find out that I represent asbestos victims, they often ask me if it’s right to sue companies when “they didn’t know back then that asbestos caused cancer.” This is a myth fostered by big business—the truth is that many companies knew asbestos was harmful but went right on selling asbestos products. I’ll save the facts about asbestos manufacturers’ first confidential testing of the health effects of asbestos in the 1930s for another blog entry, but at the bottom of this post you can see a very disturbing example of one company’s lack of interest in the health risks posed by its asbestos-containing products.
Researchers from the UK have reported on a combination treatment that could prove to be an effective treatment for sufferers of pleural mesothelioma, which is a form of cancer that is contracted through exposure to airborne asbestos dust and fibers.
Following testing and research the researchers have reported that a combination of Alimta® (pemetrexed) and Paraplatin® (carboplatin) could prove to be an effective treatment to help control the effects of this form of cancer in patients.
A study was carried out where this combination treatment was used on forty nine patients in the UK who were suffering from pleural mesothelioma. The drug treatment helped to improve disease control in nearly seventy percent of the patients.
Researchers also described the treatment as having been tolerated well and without having treatment related mortality. The average survival time for treatment patients was fourteen months, and the results of the study have been published in the specialist journal ‘Lung Cancer’.
Just a few lines to let you know how thankful I am for what you are doing for me. I am so grateful. Thank you so much, you are the greatest.– Andrine P.
Have you or someone you know been harmed or died as a result of exposure to asbestos? If so, please contact us for help and further information.
How we can help you
The people we help
How we've helped
Read & help yourself
Get help now
© 2010 Bergman Draper & Frockt, PLLC – All rights reserved